57.90
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$55.47
Offen:
$55.77
24-Stunden-Volumen:
1.13M
Relative Volume:
0.49
Marktkapitalisierung:
$8.86B
Einnahmen:
$700.35M
Nettoeinkommen (Verlust:
$461.90M
KGV:
20.18
EPS:
2.8696
Netto-Cashflow:
$-14.19M
1W Leistung:
+5.19%
1M Leistung:
+43.90%
6M Leistung:
+90.47%
1J Leistung:
+60.62%
Tg Therapeutics Inc Stock (TGTX) Company Profile
Firmenname
Tg Therapeutics Inc
Sektor
Branche
Telefon
(212) 554-4484
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
TGTX
Tg Therapeutics Inc
|
57.89 | 8.16B | 700.35M | 461.90M | -14.19M | 2.8696 |
|
VRTX
Vertex Pharmaceuticals Inc
|
523.88 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.87 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
921.67 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.22 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
191.59 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2024-10-29 | Eingeleitet | TD Cowen | Buy |
| 2023-08-02 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-26 | Fortgesetzt | Jefferies | Buy |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2018-09-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-04-25 | Eingeleitet | Jefferies | Buy |
| 2017-03-06 | Bestätigt | FBR & Co. | Outperform |
| 2016-10-06 | Fortgesetzt | Brean Capital | Buy |
| 2016-05-27 | Eingeleitet | SunTrust | Buy |
| 2015-12-01 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-19 | Bestätigt | Brean Capital | Buy |
| 2014-12-11 | Bestätigt | ROTH Capital | Buy |
| 2014-12-10 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
TG Therapeutics, Inc. Stock 12‑Month Price Target Raised to $52.14, Implies 6% Downside - TradingView
TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
TGTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $70 - GuruFocus
TG Therapeutics begins schizophrenia Phase 2 trial - grafa.com
TG Therapeutics begins trial of Briumvi for schizophrenia - Investing.com
TG Therapeutics tests BRIUMVI in 60 schizophrenia patients - Stock Titan
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance - marketscreener.com
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2? - Yahoo Finance
TGTXTG Therapeutics Inc Dividends - Finviz
TG THERAPEUTICS INC (NASDAQ:TGTX): High-Growth Momentum Meets Minervini Trend Template Technical Strength - ChartMill
TG THERAPEUTICS INC (TGTX) Stock Chart - ChartMill
Price to sales forward of TG Therapeutics, Inc. – NASDAQ:TGTX - TradingView
Price to earnings forward of TG Therapeutics, Inc. – MIL:1TGTX - TradingView
Does TG Therapeutics (NASDAQ:TGTX) Deserve A Spot On Your Watchlist? - Moomoo
TG Therapeutics Surged 88%: Time To Be More Careful (Rating Downgrade) (NASDAQ:TGTX) - Seeking Alpha
Responsive Playbooks and the TGTX Inflection - Stock Traders Daily
TGTX stock continues rally for 8 straight sessions on new BRIUMVI clinical data - MSN
NKB2 Forecast — Price Target — Prediction for 2027 - TradingView
TG Therapeutics (TGTX) soars 7.5%: Is further upside left in the stock? - MSN
TG Therapeutics Board Authorizes New $100M Share Repurchase Program - MSN
Price to earnings forward of TG Therapeutics, Inc. – NASDAQ:TGTX - TradingView
Enterprise value to EBITDA forward of TG Therapeutics, Inc. – FWB:NKB2 - TradingView
Price to book forward of TG Therapeutics, Inc. – FWB:NKB2 - TradingView
Enterprise value to EBIT forward of TG Therapeutics, Inc. – NASDAQ:TGTX - TradingView
Enterprise value to EBIT forward of TG Therapeutics, Inc. – LSX:A1JXW7 - TradingView
Price to sales forward of TG Therapeutics, Inc. – FWB:NKB2 - TradingView
Enterprise value to revenue forward of TG Therapeutics, Inc. – NASDAQ:TGTX - TradingView
TG Therapeutics, Inc. Actuals & Estimates (NASDAQ:TGTX) - TradingView
TG Therapeutics, Inc. Actuals & Estimates (MIL:1TGTX) - TradingView
Price to earnings forward of TG Therapeutics, Inc. – LSX:A1JXW7 - TradingView
Price to sales forward of TG Therapeutics, Inc. – LSX:A1JXW7 - TradingView
TGTX Forecast — Price Target — Prediction for 2027 - TradingView
TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data - Stocktwits
TG Therapeutics Inc (TGTX) Institutional Confidence - TradingKey
TG Therapeutics Stock 10-Day Winning Spree: Stock Climbs 35% - Trefis
TG Therapeutics Stock Surges 35%, With A 10-Day Winning Spree - Trefis
Jefferies Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $83 - Moomoo
TG Therapeutics, Inc. (TGTX) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth - DirectorsTalk Interviews
TG Therapeutics Stock Rockets 33% With 9-Day Winning Streak - Trefis
TG Therapeutics Stock 9-Day Winning Spree: Stock Climbs 33% - Trefis
TG Therapeutics rises on early-stage trial data for Briumvi injectable - MSN
Is TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now? - Insider Monkey
TG Therapeutics stock hits 52-week high at 54.04 USD By Investing.com - Investing.com Australia
TG Therapeutics Stock Surges 28%, With A 8-Day Winning Spree - Trefis
The Utter Rampage That Sent This Biotech Flying 79% - Investor's Business Daily
TG Therapeutics Stock Rises Thursday: What's Driving The Gains?TG Therapeutics (NASDAQ:TGTX) - Benzinga
TG Therapeutics Inc (TGTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TG Therapeutics stock hits 52-week high at 54.04 USD - Investing.com
TGTX stock up on positive phase I data for subcutaneous Briumvi - MSN
TG Therapeutics Inc (TGTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):